Page 39 - CIBEREHD-2015-eng

Research Groups
Most relevant scientific articles
roBles-diaz m., González-Jiménez a., medina-Caliz i., sTePhens C., GarCía-CorTes m., GarCía-munoz B. eT al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharma- cology and Therapeutics. 2015;41(1):116-125.
TesChke r., andrade r.J.. Drug-induced liver injury: Ex- panding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gas- troenterology. 2015;148(7):1271-1273.
Chen m., suzuki a., Borlak J., andrade r.J., luCena m.i.. Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology. 2015;63(2):503-514.
roBles-diaz m., GarCía-CorTes m., medina-Caliz i., González-Jiménez a., González-Grande r., naVarro J.m. eT al. The value of serum aspartate aminotrans- ferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver International. 2015;35(11):2474-
andrade r.J.. Reducing Risk of Severe Liver Injury in Pa- tients Treated With Isoniazid. Clinical Gastroenterology and Hepatology. 2015;13(9):1683-1685.
Highlights
GRANTS:
• FIS PI15/01440: Analysis of physico-chemical drug properties, host factors and their interaction in hepa- totoxicity phenotype presentation and outcome.
· Grant “Stabilisation programme of researchers & In- tensification of the research activity in the National Health System. Carlos III Health Institute.
· COST proposal OC-2015-2-20045 “Pro Euro DILI Net
· PLAN PROPIO UMA FOR THE CREATION OF THE- MATICS NETWORKS, denominada “Pro-Euro-DILI Registry – Creation of a multicentre and multidis- ciplinary European registry of prospective drug-in- duced liver injury cases”.
· Contract with the Spanish Medicines Agency.
TRANSFER OF SCIENTIFIC KNOWLEDGE/INNOVA- TION: Design of an Hepatotoxicity APP for iOS and androids: eDILI gives information about hepatotoxicity and calculates the indeces used in this pathology.
2482.
DEVELOPING OUR HEPATOTOXICITY NET- WORKS:
• Spanish and Latin-American DILI Registry
(www.spanishdili.uma.es; www.slatindili.uma.es).
• Prospective European Drug-Induced Liver Injury
Registry (Pro-EuroDILI Registry).
OTHERS:
• Chair of the Commision for Evaluating progress of Clinical independent Research projects ICI 2015. Member of the Executive Committee IUPHAR.
• Application for “MEP-SCIENTIST PAIRING SCHEME 2015” to interact with the deputies (members of the European Parliament).
• Prize of the Spanish Society of Pharmacology for the best Comunicación (poster). Valencia 2015.
• Director and Coordinator of the XV Course on Ad- vances in Hepatology 2015.
• Establishing Collaboration with the National Center for Toxicological Research (FDA, USA), Central Ar- kansas Veterans Healthcare System (USA) & Center of Pharmacology and Toxicology (Germany).
• Invited Speaker at International Conferences HEPA- TOLOGIA DO MILÊNIO 2015, BRAZIL; EASL/AASLD MONOTHEMATIC CONFERENCE AUTOIMMUNE HEPATITIS, LONDON 2015; JAPAN DIGESTIVE DIS- EASE WEEK 2015; 5TH SYMPOSIUM HEPATOLO- GY 2015, SWITZERLAND; NIH- ASSLD Workshop, Bethesda 2015.
Institution: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) Contact: Hospital Virgen de La Victoria. Campus Universitarios Teatinos s/n. 29010 Málaga
E.mail: [email protected] · Website: http://www.spanishdili.uma.es ; www.slatindili.uma.es
CIBEREHD I Annual report 2015 I 39